Clinical Trials Logo
  1. Home
  2. Crohn's Disease
  3. NCT00737932
  4. Details
NCT00737932 Clinical Trial

Laquinimod Phase IIa Study in Active Crohn's Disease

Crohn's Disease Clinical Trial

Official title:
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn's Disease.

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00737932
Other study ID # CD-LAQ-201
Secondary ID
Status Completed
Phase Phase 2
First received August 18, 2008
Last updated March 19, 2015
Start date May 2010
Est. completion date December 2011

Study information
Verified date March 2015
Source Teva Pharmaceutical Industries
Contact n/a
Is FDA regulated No
Health authority European Union: European Medicines Agency
Study type Interventional

Clinical Trial Summary

The study aims to evaluate the safety and clinical effect of daily oral treatment of Laquinimod capsules in active moderate to severe Crohn's disease. This study will assess Laquinimod doses of 0.5mg /day to 2 mg/day in sequential dose groups (cohorts). Laquinimod is a novel immunomodulating drug which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. for Multiple Sclerosis.

Recruitment information / eligibility
Status Completed
Enrollment 180
Est. completion date December 2011
Est. primary completion date November 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Subjects diagnosed with Crohn's disease for at least 3 months prior to screening.

2. Moderate to severe Crohn's disease patients as determined by the CDAI score

Exclusion Criteria:

1. Subjects who have had recent bowel surgery

2. Subjects with clinically significant GI obstructive symptoms

3. Subjects with a clinically significant or unstable medical or surgical condition

4. Subjects with unstable doses of standard of care medications (5-ASA, antibiotics, oral corticosteroids, immunosuppressants )

5. Women who are pregnant or nursing or who intend to be during the study period.

6. Women of child-bearing potential who do not practice an acceptable method of birth control

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Laquinimod
Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment
Other:
• placebo
Matching placebo for 8 weeks of treatment

Locations
Country Name City State
Belgium Teva Investigational Site 3711 Bonheiden
Belgium Teva Investigational Site 3712 Leuven
Belgium Teva Investigational Site 3713 Roeselare
France Teva Investigational Site 5351 Amiens Cedex 1
France Teva Investigational Site 5352 Clichy
France Teva Investigational Site 5353 La Tronche
France Teva Investigational Site 5350 Lille Cedex
France Teva Investigational Site 5354 Nice
France Teva Investigational Site 5355 Paris
Israel Teva Investigational Site 8048 Haifa
Israel Teva Investigational Site 8046 Jerusalem IL
Israel Teva Investigational Site 8047 Petach-Tikva IL
Israel Teva Investigational Site 8050 Ramat -Gan IL
Israel Teva Investigational Site 8051 Rehovot IL
Israel Teva Investigational Site 8049 Tel-Aviv IL
Italy Teva Investigational Site 3069 Roma
Italy Teva Investigational Site 3070 Roma
Italy Teva Investigational Site 3072 San Donato Milanese (MI)
Netherlands Teva Investigational Site 3819 Amsterdam
Netherlands Teva Investigational Site 3820 Rotterdam
Poland Teva Investigational Site 5361 Krakow
Poland Teva Investigational Site 5360 Warszawa
Poland Teva Investigational Site 5362 Wroclaw
Poland Teva Investigational Site 5363 Wroclaw
South Africa Teva Investigational Site 9009 Claremont, Cape Town
South Africa Teva Investigational Site 9017 Overport, Durban
South Africa Teva Investigational Site 9013 Panorama, Cape Town
Spain Teva Investigational Site 3158 Barcelona
Spain Teva Investigational Site 3164 Córdoba
Spain Teva Investigational Site 3160 Madrid
United Kingdom Teva Investigational Site 3428 Bristol
United Kingdom Teva Investigational Site 3430 Coventry
United Kingdom Teva Investigational Site 3429 Liverpool
United Kingdom Teva Investigational Site 3432 London

Sponsors (1)
Lead Sponsor Collaborator
Teva Pharmaceutical Industries

Countries where clinical trial is conducted

Belgium,  France,  Israel,  Italy,  Netherlands,  Poland,  South Africa,  Spain,  United Kingdom, 

Outcome
Type Measure Description Time frame Safety issue
Primary Safety, Tolerability, Clinical Effect - proportion of subjects in clinical remission, proportion of subjects who respond to treatment. 8 weeks No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03815851 - Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery N/A
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Completed NCT02883452 - A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis Phase 1
Recruiting NCT04777656 - Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. Phase 3
Terminated NCT03017014 - A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Recruiting NCT06053424 - Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease Phase 1
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Terminated NCT02882841 - MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients N/A
Not yet recruiting NCT02858557 - The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases N/A
Completed NCT02542917 - Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
Terminated NCT02417974 - Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT) Phase 2
Completed NCT03010787 - A First Time in Human Study in Healthy Volunteers and Patients Phase 1
Active, not recruiting NCT02316678 - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics N/A
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02193048 - Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
Completed NCT02265588 - Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD). N/A
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Recruiting NCT02395354 - Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease N/A
Completed NCT01951326 - Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease Phase 3